Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835096 | 0.78 | ALDH1A1 (0.62) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL29875554 | 0.78 | ALDH1A1 (0.62) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL29838503 | 0.77 | ALDH1A1 (0.70) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL5449341 | 0.77 | ALDH1A1 (0.70) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL5188523 | 0.77 | SMN1; SMN2 (0.68) | KMT2AL3MBTL1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL10459409 | 0.76 | ALDH1A1 (0.53) | KMT2AALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL29639347 | 0.74 | L3MBTL1 (0.59) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL20560546 | 0.74 | RAB9A (0.57) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL147200 | 0.74 | L3MBTL1 (0.59) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E | |
| SCHEMBL5718560 | 0.73 | MASP2 (0.57) | KMT2AL3MBTL1ALDH1A1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084164-B2 | Triazole derivative | ASTELLAS PHARMA, INC. (JP) | 2006-08-01 | — | — | US | disclosed |
| US-7034047-B2 | Triazole derivative | ASTELLAS PHARMA, INC. (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20060025461-A1 | Triazole derivative | ASTELLAS PHARMA INC. | 2006-02-02 | — | — | US | disclosed |
| US-20040214818-A1 | Triazole derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD., MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2004-10-28 | — | — | US | disclosed |
| US-20030216385-A1 | Triazole derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1293503-A1 | TRIAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214818-A1 | Triazole derivative | SLC18A3, SLC6A3, SLC18A2 | KMT2A 2031/4885L3MBTL1 1494/4885ALDH1A1 4027/4885 |
| US-20030216385-A1 | Triazole derivatives | SLC18A3, SLC18A2, SLC6A3 | KMT2A 2101/4885L3MBTL1 1512/4885ALDH1A1 4011/4885 |
| US-20060025461-A1 | Triazole derivative | SLC18A3, SLC6A3, SLC18A2 | KMT2A 2031/4885L3MBTL1 1494/4885ALDH1A1 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.